Tonix Pharmaceuticals Presents Data on Potential Mpox Vaccine

 TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine

New data show improved tolerability in immunocompromised animals and no evidence of spreading to blood or tissues even at high doses

Tonix’s synthetic horsepox vaccine platform has been selected by NIH’s Project NextGen for clinical testing

https://www.globenewswire.com/news-release/2024/09/09/2942687/28908/en/Tonix-Pharmaceuticals-Presented-Data-on-the-Potential-Mpox-Vaccine-TNX-801-in-Using-Synthetic-Biology-to-Battle-Mpox-Talk-at-Immunology-Symposium-at-the-University-of-Alberta.html